INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Tax withholdingVerified data

Malzahn Craig reported RGNX

Chief Technology Officer · REGENXBIO Inc. · Common Stock

Side
F
Value
$2,181
Shares
234
Price
$9.32
Executed
Sep 1, 2026
Disclosed
Sep 3, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 1 executedSep 3, 2026 disclosed

RGNX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$2K reported value · 0.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RGNX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    27.8K sh
    		Nov 1, 2026Nov 3, 2026
    traded Nov 1, 2026
    		+2dSEC FORM 4

    Evidence

    43
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Open-market purchase
    		BUY$500K
    53.4K sh
    		Aug 27, 2026Aug 27, 2026
    traded Aug 27, 2026
    		+0dSEC FORM 4

    Evidence

    47
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Open-market purchase
    		BUY$450K
    49.2K sh
    		Aug 26, 2026Aug 27, 2026
    traded Aug 26, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    69.6K sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    15.4K sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    CM
    Chan MitchellChief Financial Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    73.7K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    21
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    65.8K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    35.4K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CM
    Chan MitchellChief Financial Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    39.6K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Tax withholding
    		F$18K
    1,238 sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002062007-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 1, 2026
    Published
    Sep 3, 2026
    Ingested by INSIDER
    Nov 5, 02:19 UTC
    Last re-read
    Nov 5, 02:19 UTC

    Extracted facts

    Filer
    Malzahn Craig
    Role
    Chief Technology Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    REGENXBIO Inc.
    Ticker
    RGNX
    Shares
    234
    Price per share
    $9.32
    Value
    $2,181
    Execution date (reported)
    Sep 1, 2026
    Owned after transaction
    82.0K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 234
    • Price: $9.32

    = $2,181

    What this establishes

    Malzahn Craig filed this Form 4 reporting a tax withholding of RGNX on Sep 1, 2026. It became public on Sep 3, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Technology Officer
    Malzahn Craigcik:0002062007
    Issuer
    REGENXBIO Inc.cik:0001590877

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.